Anti-endotoxin vaccines: back to the future

Area of Science:

• Microbiology
• Immunology
• Infectious Diseases

Background:

• Gram-negative bacterial infections are a significant cause of morbidity and mortality.
• Increasing antibiotic resistance in Gram-negative bacteria limits treatment options.
• Previous attempts at novel biological therapies have yielded limited success.

Purpose of the Study:

• To re-evaluate the therapeutic potential of vaccines and antibodies against Gram-negative bacterial endotoxin.
• To explore strategies for combating infections caused by antibiotic-resistant Gram-negative bacteria.

Main Methods:

• Review of earlier studies on antibodies targeting conserved regions of Gram-negative bacterial lipopolysaccharide (LPS).
• Consideration of O-specific vaccines developed previously.
• Assessment of the potential for developing new vaccines and antibodies against both O and core LPS antigens.

Main Results:

• Antibodies targeting conserved LPS core regions showed potential therapeutic benefit.
• A subunit vaccine targeting LPS has advanced to phase 1 clinical trials.
• O-specific vaccines were developed but not widely deployed due to existing treatment options.

Conclusions:

• The rise in antibiotic resistance necessitates a renewed focus on alternative therapies.
• Vaccines and antibodies targeting Gram-negative bacterial endotoxin (LPS) represent a viable therapeutic avenue.
• Further development of both core and O-antigen directed therapies is warranted.